|
How Good is Your Supply Chain's Non-Acute Lab Strategy?Baxter announces FDA approval of Myxredlin, the first and only ready-to-use insulin for IV infusionOrtho receives CE Mark for enhanced VITROS NT-proBNP II AssayRoche expands the Global Access Program to include tests for TB, Hepatitis, HPVNew Minnesota law seeks transparency in medical billingUniversity Health System plans $500M hospital expansionMount Sinai Health System to invest $1B in facility improvementsTenet submits proposal to acquire Desert Regional Medical CenterHHS awards $750K telehealth grant to Colquitt Regional Medical CenterPremier's ProvideGx program to supply sodium bicarbonate injection to providers| Sponsored | How Good is Your Supply Chain's Non-Acute Lab Strategy?
How much does your lab strategy focus on workflow efficiency as it relates to operational, clinical, and financial feasibility? How integrated are your supply chain and lab functions? Do they work together to impact revenue, patient satisfaction, and clinical outcomes?
This chapter of McKesson’s e-book for supply chain leaders details how creating a lab strategy increases patient satisfaction and clinical compliance by balancing the economic model of a central lab with the patient care benefits of point-of-care testing.Want to get caught up? Click here to read the previous chapters for free! | | | -back to top- | | Manufacturer News | Baxter announces FDA approval of Myxredlin, the first and only ready-to-use insulin for IV infusion
Baxter International Inc (Deerfield, IL) received FDA approval of Myxredlin (Insulin Human in 0.9% Sodium Chloride Injection). Myxredlin is the first and only ready-to-use insulin for IV infusion in the hospital and other acute care settings and features an extended shelf life of 30 days at room temperature or 24 months if refrigerated in the original carton to protect from light. Myxredlin is provided in a standardized concentration of 100 units/100 mL in a flexible plastic container. This presentation helps ensure Myxredlin delivers a consistent, stable and predictable concentration with every administration, the company said. Myxredlin is indicated for use as a short-acting human insulin to improve glycemic control in adults and pediatric patients with diabetes mellitus. Myxredlin is intended for use only in acute care settings under medical supervision. Myxredlin is expected to be available from Baxter in the U.S. before the end of the year. | | | -back to top- | Ortho receives CE Mark for enhanced VITROS NT-proBNP II Assay
Ortho Clinical Diagnostics (Raritan, NJ) announced the CE Mark of an enhanced version of its VITROS NT-proBNP II assay, part of Ortho’s expansive cardiac menu. The analytical characteristics and clinical performance of the VITROS NT-proBNP II assay allow clinicians to efficiently assess heart failure patients, the company said. The assay is designed for the aid in diagnosis of heart failure and for the risk stratification of acute coronary syndrome and heart failure. It is further indicated as an aid in the assessment of increased risk of cardiovascular events and mortality in patients who have stable coronary artery disease and in the assessment of heart failure severity in patients diagnosed with heart failure. | | | -back to top- | Roche expands the Global Access Program to include tests for TB, Hepatitis, HPV
Roche (Switzerland) announced the Global Access Program is expanding beyond HIV to include Mycobacterium tuberculosis (MTB), Hepatitis B and C (HBV and HCV), and Human Papillomavirus (HPV) for low and middle income country programs where the disease burden is the highest. In total, the Global Access Program now includes molecular diagnostics for HIV-1 viral load, HIV-1 and HIV-2 early infant diagnosis, the cobas Plasma Separation Card - an innovative plasma collection device, MTB and MTB - RIF/INH, Hepatitis B and C, and Human Papillomavirus. All these assays run on the cobas 4800/6800/8800 platforms for various testing volume needs enabled by the cobas Plasma Separation Card that transports samples from remote areas/sites to the central lab for further processing. | | | -back to top- | | Government News | New Minnesota law seeks transparency in medical billing
Minnesota legislation to protect patients from the surprise aspect of medical bills will take effect August 1. The legislation was written by state Sen. Rich Draheim, R-Madison Lake, and signed by Gov. Tim Walz. Under the bill, hospital or health system-based clinics will be required to post notices at their physical and online locations to notify patients that the patient may be on the hook for higher out-of-pocket costs due to facility fees (aka provider-based billing). The goal is to improve healthcare cost transparency but consumer advocate Buddy Robinson, director of the Minnesota Citizens Federation Northeast, told brainerddispatch.com that he doesn't expect the legislation to have a huge effect as far as empowering patients and promoting competition. | | | -back to top- | | Hospital and IDN News | University Health System plans $500M hospital expansion
University Health System (San Antonio, TX) is preparing for a $500 million expansion at its main South Texas Medical Center campus. The project will feature a 12-story tower for women's and children's and women's services and two Eds – one for OB-GYN patients and another for children. The project will include 268 patient rooms, family resource centers, a pediatric rehab gym and a level-4 maternity center. It is expected to be completed in late 2022. | | | -back to top- | Mount Sinai Health System to invest $1B in facility improvements
Mount Sinai Health System plans to invest $1 billion into facility upgrades and expansions in downtown New York City. The $1 billion investment includes $600 million for rebuilding Mount Sinai Beth Israel Hospital. The health system filed a certificate of need application with the New York State Department of Health to build a replacement facility for Mount Sinai Beth Israel Hospital, construct a new behavioral health center and upgrade the New York Eye and Ear Infirmary of Mount Sinai. The new hospital will have 70 beds and an emergency room. Construction is expected to start in 2020 and open in 2023. The planned $140 million behavioral health center will house 135 beds. | | | -back to top- | Tenet submits proposal to acquire Desert Regional Medical Center
Tenet Healthcare (Dallas, TX) has submitted a proposal to the Desert Healthcare District to purchase Desert Regional Medical Center (Palm Springs, CA). The Desert Healthcare District owns Desert Regional Medical Center and Tenet is running the hospital under a 30-year lease which expires in 2027. Under Tenet's proposal, Tenet would make a financial commitment of between $318 million and $380 million. That total includes a base price of $120 million to purchase the hospital at fair-market value, $119 million to $180 million for seismic upgrades, and an $80 million investment in local healthcare services and capital projects over the next eight years. | | | -back to top- | HHS awards $750K telehealth grant to Colquitt Regional Medical Center
The U.S. Department of Health and Human Services (HHS) has granted Hospital Authority of Colquitt County (Moultrie, GA) $750,000 in funding for telehealth technology and equipment to increase healthcare access for rural patients. Hospital Authority of Colquitt County oversees 99-bed Colquitt Regional Medical Center. The funding will also be applied toward Hospital Authority of Colquitt County's efforts to achieve accreditation through the Accreditation Council for Graduate Medical Education, which is a nonprofit that evaluates and accredits medical residency and internship programs. The grant is part of $20 million that HHS awarded to 27 different U.S. healthcare organizations in support of developing new rural residency programs. | | | -back to top- | | GPO News | Premier's ProvideGx program to supply sodium bicarbonate injection to providers
Premier Inc (Charlotte, NC), through its ProvideGx program, has partnered with Exela Pharma Sciences LLC, to supply sodium bicarbonate injection to healthcare providers, a drug that has been in shortage in the U.S. for nearly two years. Limited supplies of the drug today are being imported from Australia under special U.S. Food and Drug Administration (FDA) rules that apply in shortages, but the costs for the imported product are 300% higher than the U.S. alternatives. Exela Pharma Sciences is a new producer of sodium bicarbonate, having just received approval for its Abbreviated New Drug Application (ANDA) from the FDA to begin manufacturing. As such, they will be an entirely new source of supply, helping fulfill the increased demand needs that today’s incumbents are unable to accommodate. Learn more here. | | | -back to top- |
|
|
|
|